mRNA vaccines encoding variant forms of Sm-TSP-2 confer protective immunity against Schistosoma mansoni Authors: Athos Silva de Oliveira, Sevan Alwan, Philip T. LoVerde, Ramiz Shaheed, Pranav Mandyam, Rakesh Adhikari, Peter Hotez, Maria Elena Bottazzi, Jeroen Pollet Published: 2025 ABSTRACT This study explored the development and evaluation of mRNA vaccine candidates targeting Schistosoma mansoni tetraspanin-2 (Sm-TSP-2). We designed constructs encoding either full-length Sm-TSP-2, or its large extracellular loop (EC2) domain in secretory, membrane-anchored, or cytosolic forms. In a murine model, the secreted and membrane-anchored versions of Sm-TSP-2-EC2 induced the highest antigen-specific antibody titers. These two construct designs, along with full-length Sm-TSP-2 mRNA, also significantly reduced adult worm and egg burden compared to controls. The membrane-anchored Sm-TSP-2-EC2 mRNA was the most effective, lowering worm and egg burdens by 66.7% and 66.9%, respectively. Protective responses induced by the mRNA vaccines were comparable to those elicited by the Sm-TSP-2-EC2 protein formulated with Alum. Histopathological analysis revealed smaller hepatic granulomas surrounding worm eggs, supporting the immunopathological benefit of vaccination. Using a systematic mRNA-based approach, we optimized the presentation of the Sm-TSP-2-EC2 and demonstrated that extracellular exposure of EC2 is essential for eliciting a protective response. Introduction The development of vaccines against helminth parasites, such as hookworms and schistosomes, faces unique challenges due to significant biological and immunological barriers not commonly encountered with other pathogens1–3. Despite the complexity, significant progress has been made, with several anthelminthic vaccines advancing through clinical development for schistosomiasis, including a candidate targeting Schistosoma mansoni tetraspanin 2 (Sm-TSP-2) protein4,5. Tetraspanins are a highly conserved family of transmembrane proteins with four-pass membrane domains and two extracellular loops: the small extracellular loop (EC1) and the large extracellular loop (EC2)6. Sm-TSP-2 plays an essential structural role in the development, maturation and maintenance of the worm tegument7. Due to the insoluble nature of full-length Sm-TSP-2, only its EC2 has been expressed as a recombinant protein8–12. Consequently, most studies employing recombinant Sm-TSP-2-EC2 refer to this domain simply as Sm-TSP-2. Recombinant Sm-TSP-2-EC2 has been used to generate antibodies that confirmed Sm-TSP-2 localization in the outer tegument of adult S. mansoni, and also has served as an antigen in both preclinical and clinical vaccine studies10. The Sm-TSP-2-EC2 structure has been resolved, enabling the identification of its interaction with other parasite proteins13. In mice, immunization with Sm-TSP-2-EC2 protein, formulated with Freund’s adjuvant, resulted in a 57% reduction of adult worm burden and a 64% reduction in liver egg burden10. In a phase 1, double blind clinical trial, conducted in a non-endemic area, an Alum-adjuvanted Sm-TSP-2-EC2 recombinant protein vaccine was safe and well tolerated14. Furthermore, in a randomized, controlled Phase 1b clinical trial involving healthy Brazilian adults living in an endemic region, the vaccine was safe, minimally reactogenic, and elicited significant IgG seroconversion15. While recombinant protein vaccines based on Sm-TSP-2-EC2 have shown immunogenicity and protection in schistosomiasis challenge models, further improvements in efficacy may still be achieved for optimal protective outcomes. Recent advancements in RNA technology have revolutionized the prevention and mitigation of infectious diseases by enabling the rapid development of effective, scalable, and customizable vaccines16. RNA vaccines facilitate the expression of full-length antigens and allow the incorporation of signal sequences that can modulate the antigen trafficking in recipient cells and tissues17,18. While switching to an mRNA platform alone may not achieve sterilizing immunity, we hypothesized that Sm-TSP-2-based mRNA vaccines could induce protective efficacy comparable to or exceeding that of recombinant protein vaccines. The streamlined and antigen-independent manufacturing process of mRNA platforms makes them particularly suitable for multivalent vaccine strategies, either incorporating multiple schistosome antigens, or vaccines that can target multiple co-endemic parasites19. We recently developed mRNA vaccine candidates encoding hookworm antigen Na-GST-1, engineered for cytosolic accumulation, secretion, or plasma membrane (PM) anchoring20. Despite differences in protein expression among these constructs, antibody titers and T cell populations did not scale proportionally with protein levels, reinforcing that immune responses are more influenced by factors like antigen localization and processing. In this study, we evaluated the efficacy of four mRNA vaccine candidates encoding either the full-length Sm-TSP-2 (native) or the Sm-TSP-2-EC2 domain targeted to different cellular compartments as cytosolic, secreted, or PM-anchored antigen. Mice were immunized with each mRNA formulation, and vaccine performance was evaluated by measuring Sm-TSP-2-EC2-specific IgG responses, as well as by assessing worm burden, egg burden, and hepatic granuloma size following challenge. A recombinant Sm-TSP-2-EC2 protein was included as a benchmark control. Results mRNAs enable the in-vitro expression of full-length Sm-TSP-2 and Sm-TSP-2-EC2 variants In addition to the Sm-TSP-2-EC2 mRNA, which encodes the same EC2 domain as the recombinant protein previously used in preclinical and clinical trials (referred to in this study as rSm-TSP-2-EC2 protein), two additional mRNAs were designed to investigate the impact of antigen localization: a secreted version (sSm-TSP-2-EC2), containing a signal peptide for secretion, and a PM-anchored version (pmSm-TSP-2-EC2), incorporating signal peptide for endoplasmic reticulum import and a CD55 glycosylphosphatidylinositol (GPI) anchor signal (Fig. 1a). A fourth construct encoding full-length Sm-TSP-2 mRNA was also designed. All mRNAs included a C-terminal FLAG, except pmSm-TSP-2-EC2, which contains an N-terminal FLAG to preserve proper detection by anti-FLAG. All mRNAs were successfully made in-house (Fig. 1b).Fig. 1mRNA production and in vitro characterization.a Schematic representation of Sm-TSP-2 showing its four-pass transmembrane domains and two extracellular loops, with EC2 highlighted by dashed lines. In the mRNA schemes, “G” represents CleanCap structure and gray regions indicate untranslated regions (UTRs). “SP” refers to signal peptide for protein secretion (sSm--TSP-2-EC2) or endoplasmic reticulum import (pmSm-TSP-2-EC2), while GPI indicates CD55 glycosylphosphatidylinositol signal sequence. Schematic created with Biorender.com. b Integrity of synthesized mRNA assessed by agarose gel electrophoresis; 400 ng of each mRNA were loaded on a 1.5% agarose gel. c Confirmation of protein size by Western blot using anti-FLAG after transfection of mRNAs in DC2.4 cells. d Subcellular localization of expressed proteins by immunocytochemistry in mRNA-transfected DC2.4 cells. In fixed and permeabilized cells, Alexa Fluor 488-conjugated mouse anti-FLAG can access all cellular compartments, including internal membrane-bound organelles. In contrast, in cells fixed without permeabilization (“Fix only”), the antibody is restricted to the cell surface and cytosol. mRNA production and in vitro characterization. a Schematic representation of Sm-TSP-2 showing its four-pass transmembrane domains and two extracellular loops, with EC2 highlighted by dashed lines. In the mRNA schemes, “G” represents CleanCap structure and gray regions indicate untranslated regions (UTRs). “SP” refers to signal peptide for protein secretion (sSm--TSP-2-EC2) or endoplasmic reticulum import (pmSm-TSP-2-EC2), while GPI indicates CD55 glycosylphosphatidylinositol signal sequence. Schematic created with Biorender.com. b Integrity of synthesized mRNA assessed by agarose gel electrophoresis; 400 ng of each mRNA were loaded on a 1.5% agarose gel. c Confirmation of protein size by Western blot using anti-FLAG after transfection of mRNAs in DC2.4 cells. d Subcellular localization of expressed proteins by immunocytochemistry in mRNA-transfected DC2.4 cells. In fixed and permeabilized cells, Alexa Fluor 488-conjugated mouse anti-FLAG can access all cellular compartments, including internal membrane-bound organelles. In contrast, in cells fixed without permeabilization (“Fix only”), the antibody is restricted to the cell surface and cytosol. Following mRNA transfection in DC2.4 cells, Western blot (WB) analysis confirmed expression of proteins at their expected molecular sizes (Fig. 1c). Subcellular localization was observed by immunocytochemistry (Fig. 1d). Both Sm-TSP-2 and Sm-TSP-2-EC2 are localized predominantly to the cytosol, with Sm-TSP-2-EC2 also observed in the nucleus likely due to passive diffusion enabled by its small size (the nucleus is not seen in fixed-and-permeabilized cells). sSm-TSP-2-EC2 showed clear ER import as indicated by negligible intracellular staining in non-permeabilized cells. In contrast, pmSm-TSP-2-EC2 was clearly localized to the cell surface, consistent with successful GPI anchoring. Interestingly, the expression of pmSm-TSP-2-EC2 led to visible cell aggregation, potentially reflecting the role of Sm-TSP-2 as a tetraspanin scaffold protein. This suggests that the EC2 domain retains its native protein–protein interaction capabilities, even anchored by GPI. Sm-TSP-2 EC2 extracellular exposure by using signal sequences boosts IgG titers After in vitro validation, mRNAs were formulated into lipid nanoparticles (LNPs) as described in the Methods. To assess humoral immunogenicity and protective efficacy, 49 female mice were randomly assigned to seven groups (n = 7 per group) and immunized with one of the four Sm-TSP-2 mRNA vaccine candidates, or with rSm-TSP-2-EC2 protein formulated in Alum (Fig. 2a). Two control groups received either eGFP mRNA or saline. An Alum-only control was not included to minimize animal use and because prior murine S. mansoni studies have not shown protection with Alum alone21. Blood samples were collected prior to the prime and boost immunizations, as well as before challenge with 80 S. mansoni cercariae (Fig. 2b). EC2-specific titers were measured in the mouse sera by ELISA using plates coated with rSm-TSP-2-EC2 protein. The experiment was independently repeated twice with one modification: in the first study, mice group 3 received 10 µg of Sm-TSP-2 mRNA, whereas in the second study, they received an equimolar dose of Sm-TSP-2 mRNA (20 µg) relative to the 10 µg Sm-TSP-2-EC2 mRNA dose. As no significant differences were observed between the two doses, data from both experiments were pooled for selected analyses presented throughout the manuscript.Fig. 2Sm-TSP-2-EC2-specific IgG responses following immunizations.a Overview of the seven mouse groups, including the doses administered per immunization. b Schematic timeline of immunization and challenge procedures (created with Biorender.com). c Sm-TSP-2-EC2-specific IgG titers measured by ELISA. Results were pooled from two independent experiments (14 mice per group), except for the Sm-TSP-2 group, which received a 20-µg equimolar dose (relative to Sm-TSP-2-EC2) in the second experiment. d Sm-TSP-2-EC2-specific IgG1 and IgG2a titers measured by ELISA in samples from the second animal study (7 mice per group). Each data point represents the geometric mean of technical duplicates. Error bars represent the geometric standard deviation in both directions. The dotted horizontal lines represent the cutoff value for ELISA. Statistical analysis was conducted using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test with correction for multiple testing. Groups that do not share a letter differ significantly (p < 0.05). Sm-TSP-2-EC2-specific IgG responses following immunizations. a Overview of the seven mouse groups, including the doses administered per immunization. b Schematic timeline of immunization and challenge procedures (created with Biorender.com). c Sm-TSP-2-EC2-specific IgG titers measured by ELISA. Results were pooled from two independent experiments (14 mice per group), except for the Sm-TSP-2 group, which received a 20-µg equimolar dose (relative to Sm-TSP-2-EC2) in the second experiment. d Sm-TSP-2-EC2-specific IgG1 and IgG2a titers measured by ELISA in samples from the second animal study (7 mice per group). Each data point represents the geometric mean of technical duplicates. Error bars represent the geometric standard deviation in both directions. The dotted horizontal lines represent the cutoff value for ELISA. Statistical analysis was conducted using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test with correction for multiple testing. Groups that do not share a letter differ significantly (p < 0.05). sSm-TSP-2-EC2 and pmSm-TSP-2-EC2 mRNAs induced the highest antigen-specific IgG titers, comparable to those induced by the rSm-TSP-2-EC2 protein formulated with Alum (Fig. 2c). Although IgG titers were elevated in groups immunized with Sm-TSP-2 and Sm-TSP-2-EC2 mRNAs compared to the eGFP mRNA control, the differences did not reach statistical significance, indicating high variability or modest immunogenicity. These results collectively suggest that extracellular exposure, either by secretion or anchoring, is critical for robust humoral immunogenicity when Sm-TSP-2-EC2 is used as an antigen in mRNA vaccine formulations. It is important to highlight that ELISA plates were coated with rSm-TSP-2-EC2 protein, and therefore, the assay did not detect antibodies targeting epitopes outside the EC2 domains that may have been induced by Sm-TSP-2 mRNA. During the acute schistosome infection in mice, the immune response is predominantly Th1 but shifts towards a Th2 profile upon the onset of egg deposition22,23. Given that murine IgG1 and IgG2a subclasses are generally associated with Th2 and Th1 responses24, respectively, these IgG subclasses were quantified in serum samples from the second animal study. The highest IgG1 titers were observed in mice immunized with sSm-TSP-2-EC2 and pmSm-TSP-2-EC2 mRNAs, and rSm-TSP-2-EC2 protein (Fig. 2d). Only Sm-TSP-2 and pmSm-TSP-2-EC2 mRNAs elicited statistically significant IgG2a titers compared to saline and eGFP mRNA. These findings suggest that intracellular antigen localization from Sm-TSP-2 mRNA may promote a more Th1-skewed response, while GPI anchoring of pmSm-TSP-2-EC2 mRNA supports a more balanced Th1/Th2 profile. pmSm-TSP-2-EC2 mRNA induces the greatest reduction in egg and worm burden after vaccination Three weeks after the boost immunization, each mouse was challenged with 80 S. mansoni cercariae and sacrificed 45 days later, corresponding to the time when parasites reach full maturity. Egg burden was determined by counting the number of eggs per gram of liver tissue, and adult worms were recovered through portal and mesenteric vein perfusion. All mRNA vaccine groups, except Sm-TSP-2-EC2 mRNA group, showed a significant reduction in egg burden compared to the saline and eGFP mRNA controls (Fig. 3a). A similar trend was observed for adult worm counts, with Sm-TSP-2-EC2 being again the only group that did not significantly differ from the controls. The pmSm-TSP-2-EC2 mRNA group showed the greatest numerical reduction in both egg and worm burdens relative to the eGFP mRNA group, although these differences were not statistically significant compared to the other vaccine groups, except in comparison to Sm-TSP-2-EC2 mRNA for adult worm counts (Fig. 3a, b). These findings are mostly paralleled with EC2-specific IgG titers, suggesting a correlation between humoral immune responses and parasite burden reduction. In contrast, the protective effect induced by Sm-TSP-2 mRNA appeared to involve immune responses targeting epitopes also outside the EC2 domain or not available when EC2 is expressed alone.Fig. 3Reduction in egg and adult worm burdens following immunization.a Parasite burden counts from two independent experiments (14 mice per group; in the second experiment, the liver from one mouse was removed for histopathology and therefore excluded from egg counts). Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test with correction for multiple testing. Data points represent the arithmetic mean, and error bars indicate the arithmetic standard deviation in both directions. Groups that do not share a letter differ significantly (p < 0.05). b Percent reductions in worm and egg counts were calculated relative to the eGFP mRNA group. Reduction in egg and adult worm burdens following immunization. a Parasite burden counts from two independent experiments (14 mice per group; in the second experiment, the liver from one mouse was removed for histopathology and therefore excluded from egg counts). Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test with correction for multiple testing. Data points represent the arithmetic mean, and error bars indicate the arithmetic standard deviation in both directions. Groups that do not share a letter differ significantly (p < 0.05). b Percent reductions in worm and egg counts were calculated relative to the eGFP mRNA group. Sm-TSP-2/EC2 mRNA vaccination may reduce granuloma size surrounding S. mansoni eggs Histopathological analysis was performed on one randomly selected mouse per group, as the remaining livers were used for quantification of eggs. As expected, granulomas surrounding S. mansoni embryonated eggs were observed in all groups (Fig. 4a). Although mice immunized with Sm-TSP-2, sSm-TSP-2-EC2, pmSm-TSP-2-EC2 mRNAs, and rSm-TSP-2-EC2 protein displayed a trend toward reduced mean granuloma size compared with controls (Fig. 4b), statistical significance was seen only for pmSm-TSP-2-EC2 mRNA. Because granulomas were scarce in some treatment groups, only six granulomas per liver could be measured to calculate mean granuloma size, which may have reduced the statistical power to detect more subtle differences. The reduction trend in granuloma size mirrored decreases in egg and worm burdens, suggesting the possibility that immunization with Sm-TSP-2/EC2 reduces parasite load but also attenuates the pathological tissue responses associated with S. mansoni infection.Fig. 4Morphological aspects and egg-induced hepatic granulomas in vaccinated and unvaccinated mice.a Representative hematoxylin- and eosin-stained liver sections collected 45 days post-infection. Green rectangles indicate a scale of 20 µm. b Each data point represents the area (µm2) of one of six granulomas measured from the liver of a single mouse per group. Error bars show the standard error of the mean (SEM). Statistical analysis was conducted using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test with correction for multiple testing. Groups that do not share a letter differ significantly (p < 0.05). Morphological aspects and egg-induced hepatic granulomas in vaccinated and unvaccinated mice. a Representative hematoxylin- and eosin-stained liver sections collected 45 days post-infection. Green rectangles indicate a scale of 20 µm. b Each data point represents the area (µm2) of one of six granulomas measured from the liver of a single mouse per group. Error bars show the standard error of the mean (SEM). Statistical analysis was conducted using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test with correction for multiple testing. Groups that do not share a letter differ significantly (p < 0.05). Discussion This study demonstrates that mRNA vaccines encoding full-length Sm-TSP-2 or Sm-TSP-2-EC2 can elicit antigen-specific antibody responses and reduce parasite burden in a murine model of S. mansoni infection. By engineering mRNAs to expose Sm-TSP-2-EC2 extracellularly, either through secretion or plasma-membrane-anchoring, we showed that both immunogenicity and protective efficacy are significantly enhanced compared to cytosolic EC2 expression. These responses were comparable to those induced by the benchmark recombinant Sm-TSP-2-EC2 protein formulated with Alum. These findings are particularly relevant for the inclusion of Sm-TSP-2-EC2 as a core component in future multivalent mRNA vaccine development strategies. Unlike protein subunit vaccines, which often require buffer compatibility and formulation optimization for co-formulating multiple antigens, mRNA vaccines offer greater flexibility by allowing co-formulation/delivery of multiple transcripts or the use of polycistronic constructs in a single injection. To our knowledge, this study represents the first preclinical evaluation of full-length Sm-TSP-2 as a vaccine candidate. Previous recombinant protein-based vaccine studies have referred to the extracellular loop 2 domain (Sm-TSP-2-EC2) simply as Sm-TSP-2. Although (cytosolic) Sm-TSP-2 mRNA elicited stronger immunogenicity and protective efficacy than (cytosolic) Sm-TSP-2-EC2 mRNA, it did not outperform sSm-TSP-2-EC2 and pmSm-TSP-2-EC2 mRNAs. These results indicate that extracellular exposure of EC2 by the addition of signal sequences in mRNA vaccines greatly improved the humoral immunity and reduced parasite burden. Similar conclusions were drawn in other mRNA vaccine studies, where inclusion of signal peptides or GPI anchors improved antigen presentation and immunogenicity18,20,25. Our results also reinforce previous findings that EC2 harbors the dominant B-cell epitopes of Sm-TSP-2, and that expression of the Sm-TSP-2-EC2 is enough to induce protective immunity in mice10,26. A limitation of the present study is that protection was evaluated only 3 weeks after immunization, a standard acute-challenge window, and therefore does not directly address durability. Future work should assess delayed challenges together with longitudinal memory readouts of bone-marrow antibody-secreting cells, EC2-specific memory B cells, and antigen-specific CD4+ and CD8+ T-cell subsets. Mechanistically, anchoring EC2 to the plasma membrane via the GPI signal (pmSm-TSP-2-EC2) was associated with the aggregation of DC2.4 cells. This effect is consistent with the scaffold properties of tetraspanins, as the EC2 domain is known to mediate lateral interactions with other membrane proteins and promote the formation of tetraspanin-enriched microdomains13. The fact that aggregation occurred even when EC2 was presented in a heterologous GPI-anchored context suggests that the domain has retained aspects of its native protein-protein interaction capacity. Despite its parasitic origin, Sm-TSP-2 EC2 likely shares structural determinants that permit heterotypic interactions within mammalian membranes, potentially engaging with tetraspanins or partner proteins in mouse cells. Such interactions can have immunological relevance, as increased local antigen density and stabilized surface presentation might enhance B-cell receptor crosslinking and facilitate uptake by antigen-presenting cells. These characteristics may help explain the improved responses observed with membrane-anchored EC2 relative to cytosolic EC2. In addition to Sm-p80, Sm14, Sh28GST, Sm-TSP-2 remains one of the few Schistosoma antigens that advanced through human clinical development27–31. Much of the work has used protein-in-adjuvant formulations, typically Alum, which predominantly induce Th2-skewed immune responses. Here, we demonstrated that pmSm-TSP-2-EC2 mRNA vaccine encoding membrane-tethered EC2 not only reproduces the immunogenicity of the subunit protein vaccine but may also promote a more balanced Th1/Th2 profile, as evidenced by the presence of IgG2a, a Th1-associated subclass. Comparable mixed subclass responses have been reported in mice immunized with other GPI-anchored antigens18,20. Although human IgG subclasses do not map directly onto Th polarization as observed in mice, individuals naturally resistant to S. mansoni in endemic regions of Brazil exhibited higher levels of IgG1 and IgG3 against recombinant Sm-TSP-2-EC2 than chronically infected individuals10. Importantly, human IgG1 and IgG3 are cytophilic antibodies associated with protective effector functions32. Vaccination with either mRNA constructs or rSm-TSP-2-EC2 protein appeared to reduce hepatic granuloma size, with pmSm-TSP-2-EC2 mRNA inducing a statistically significant reduction. Similar findings have been reported in studies using Sm-TSP-2-EC2 (as a subunit protein or DNA vaccine) and Sm-p80, where reductions in worm and egg burdens were accompanied by attenuated granulomatous responses in the liver33–35. This effect may be due to decreased egg deposition, which limits antigen availability and subsequently reduces immune cell recruitment and cytokine production required for granuloma formation36. Alternatively, or in combination, Sm-TSP-2 vaccination may directly increase Th1 lymphocytes subsets, which release cytokines that help reduce granulomatous pathology by counteracting excessive Th2-mediated inflammation37. In conclusion, this work provides evidence that strategic design of mRNA constructs to control antigen localization can enhance both the magnitude and quality of the immune response against helminth infections. Given the continued need for effective schistosomiasis vaccines and the practical advantages of mRNA platforms, our results support further preclinical evaluation of these mRNA vaccine candidates. Future research should focus on long-term protection, cellular immunity, and dose optimization. Moreover, these vaccines should be evaluated in combination with other previously proven antigens, such as Sm14 and Sm-p80, as well as newly identified targets to explore potential synergistic effects and advance the development of a multivalent schistosome or multi-helminth vaccine38–41. Methods Ethic statement All animal procedures were conducted in accordance with institutional and federal regulations, following review and approval by the UT Health San Antonio Institutional Animal Care and Use Committee under protocol #4061201100S7AR. RNA production Human codon-optimized Sm-TSP-2 and EC2 (GenBank: AF521091) were cloned into plasmid backbones containing T7 promoter, 5’ untranslated region (UTR), Kozak sequence, 3’ UTR, and poly(A) tail. Human IgG signal peptide was added upstream EC2 for antigen secretion. For PM-anchoring, EC2 was flanked by albumin signal peptide and a CD55 GPI attachment sequence. FLAG tag was added to the N-terminus (following the signal peptide) for PM-anchored EC2, and to the C-terminus of all other constructs. Plasmids were linearized and used as templates for in-vitro transcription following the protocol of CleanCap AG (Trilink Biotechnologies) and substituting rUTP for m1ΨTP. Template DNA was degraded with DNAse I-XT (New England Biolabs), and the synthesized mRNA was purified using silica-based spin columns. mRNA integrity was evaluated by incubating samples at 70 °C for 10 min and then ice for 5 min. Samples were loaded into 1.5% agarose gel. In vitro mRNA expression analysis DC2.4 murine dendritic cells were cultured in RPMI 1640 + L-glutamine supplemented with 10% fetal bovine serum, 1 mM non-essential amino acids, 10 mM HEPES, 55 µM beta-mercaptoethanol, and antibiotics. Cells were maintained at 37 °C in a humidified incubator with 5% CO2. For transfection, cells were seeded the day before and transfected with mRNA-Lipofectamine MessengerMAX complexes [Thermo Fisher Scientific (TFS)] according to the manufacturer’s instructions. Complete protocols for immunocytochemistry (IC) and Western blot (WB) were published elsewhere20. Briefly, for immunocytochemistry, approximately 1.25 × 105 DC2.4 cells were seeded per well in a 24-well plate and transfected with 250 µg mRNA. After 20 h, cells were fixed with Cytofix Fixation Buffer or fixed and permeabilized with Cytofix/Cytoperm Buffer (BD, Franklin Lakes, NJ). After washing, cells were stained with Alexa Fluor 488-conjugated anti-FLAG monoclonal antibody (TFS, Cat. MA1-142-A488, 1:250) and imaged using an inverted fluorescence microscope. For WB analysis, 2.5 × 105 DC2.4 cells were seeded per well in a 12-well plate and transfected with 500 ng mRNA. Cells were lysed with RIPA buffer and protein concentration was quantified by BCA assay (TFS). In addition, samples were also resolved on SDS-PAGE gel, transferred, and probed with anti-FLAG M2 (MilliporeSigma, Cat. F3165, 1:1000) as primary antibody and alkaline phosphatase-conjugated goat anti-mouse (KPL, Cat. 5220-0357, 1:3000) as secondary antibody to confirm protein sizes. mRNA-LNP formulation and characterization mRNAs were formulated into lipid nanoparticles (LNP) with Genvoy ILM lipid reagent (Precision Nanosystems) at a nitrogen-to-phosphate ratio of 4:1 on a NanoAssemblr Ignite™ instrument (Precision Nanosystems). The resulting mRNA/LNP complexes were concentrated using 30 kDa spin filter columns and sterilized by passage through 0.2 µm disk filters. Particle size and polydispersity were evaluated by dynamic light scattering using a Zetasizer Nano ZS90 (Malvern Panalytical), confirming an average LNP size of 90 nm and a polydispersity index below 15%. mRNA concentration was quantified using a RiboGreen RNA Assay kit (TFS). Detergent disruption with Triton X-100 verified that over 85% of the mRNA was successfully encapsulated in all formulations. Final vaccine formulations were diluted to 200 µg/ml mRNA in sterile 8% sucrose PBS. rSm-TSP-2-EC2 protein rSm-TSP-2-EC2 protein was previously produced in Pichia pastoris as published elsewhere8,9. For immunization, the protein was adjuvanted with Alhydrogel (Alum) (Croda) in a glucose-imidazole buffer (15% glucose, 2 mM phosphate, 10 mM imidazole, pH 7.4). Immunization, sampling, and challenge Two independent experiments were performed for immunization and challenge. A total of 49 female BALB/c mice (Envigo/Charles River), aged 4–5 weeks, were divided in 7 groups (n = 7 per group, 3 or 4 animals per cage). Group sizes were guided by prior preclinical mRNA vaccine studies from our group and aligned with the principle of reduction20. Prime and boost immunizations, as well as the parasite challenge, occurred three weeks apart. Mice were sacrificed 45 days after the challenge. mRNAs were administered at 10 µg per dose, except for Sm-TSP-2 mRNA, which was administered at 20 µg per dose in the second study. rSm-TSP-2-EC2 protein was administered at 25 µg, adsorbed onto 160 µg Alhydrogel. Blood samples were collected via retro-orbital bleeding procedures two days before each immunization and the challenge. Each mouse was challenged with 80 S. mansoni cercariae. At the time of sacrifice, adult worms were collected by mesenteric vein perfusion, and livers were harvested for egg burden and histopathological analyses. ELISA Ninety-six-well flat bottom plates were coated overnight at 4 °C with 100 µl of 0.25 µg/ml rSm-TSP-2-EC2 protein diluted in KPL coating solution (SeraCare Life Sciences). Plates were then blocked with 200 µl dilution buffer (0.1% BSA in PBST) for two hours at room temperature. After a single wash with PBST, wells were incubated in duplicate with 100 µl of serially diluted sera for 2 h at room temperature. Mouse sera were serially diluted three-fold, ranging from 1:200 to 1:2,869,781,400 in dilution buffer. Naïve mouse serum was included in all plates, to establish background and cutoff values. Following incubation, plates were washed four times and incubated for 1 h at room temperature with 100 µl of HRP-conjugated secondary antibodies (goat anti-mouse IgG, IgG1 or IgG2a; Lifespan Bioscience) in dilution buffer. After five washes, 100 µl TMB substrate was added to each well and developed for 15 min. Reactions were stopped with 100 µl 1 M HCl, and absorbance was measured at 450 nm using a BioTek Epoch 2 spectrophotometer (Agilent). Duplicate readings were averaged, and titers were calculated using a four-parameter logistic regression curve. The titer cutoff was defined as the mean absorbance of naïve serum controls plus three times the standard deviation. ELISA was performed in a blinded manner, with the experimenter unaware of the treatment group corresponding to each mouse serum sample during analysis. Data was plotted and statistical analyses were performed using GraphPad Prism software. Adult worm and egg counts Harvested worms were cultured in 2 ml DMEM supplemented with 10% FBS and antibiotic-antimycotic solution. Worms were manually sorted and counted under a dissecting stereomicroscope as previously described42. To estimate the egg burden, livers were removed, weighed, and 1 mg of each was digested in 10 ml of 5% KOH overnight at 37 °C. The number of eggs per gram of tissue was determined by light microscopy at 40x magnification as previously described43. Data was plotted and statistical analyses were performed using GraphPad Prism software. Histopathology analysis After perfusion, livers (one representative per group) were harvested, fixed in 70% ethanol, and processed for hematoxylin and eosin staining. Liver histopathology was assessed based on granuloma structure and size. To quantify average granuloma size, six well-defined granulomas per liver were selected, excluding fused granulomas (containing more than one egg) and those with unclearly visible or destroyed eggs. Tissue sections were examined under a Zeiss Axio Imager Z1 microscope, and measurements were performed by outlining granuloma boundaries at 4x magnification using ZEN software measurement tool for automatic area calculation. The histopathology evaluation was conducted in a blinded manner; the evaluator was unaware of the specific purpose of the measurements during the analysis. Data was plotted and statistical analyses were performed using GraphPad Prism software. Supplementary information ARRIVE Checklist - E10 Pollet 2025 ARRIVE Checklist - E10 Pollet 2025